Twenty-Year Survival in Glioblastoma

A Case Report and Molecular Profile

Christina Maria Sperduto, Arnab Chakravarti, Ken Aldape, Peter Burger, Gail Bender Papermaster, Paul Sperduto

Research output: Contribution to journalArticle

Abstract

Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.

Original languageEnglish (US)
Pages (from-to)1162-1165
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume75
Issue number4
DOIs
StatePublished - Nov 15 2009

Fingerprint

Glioblastoma
prognosis
Survival
profiles
Transferases
Survivors
Molecular Biology
tumor suppressor genes
Genetic Testing
Tumor Suppressor Genes
Research
Epidermal Growth Factor Receptor
Protein Kinases
electric batteries
proteins
Therapeutics

Keywords

  • Glioblastoma
  • Molecular Profile
  • Outcomes
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Sperduto, C. M., Chakravarti, A., Aldape, K., Burger, P., Papermaster, G. B., & Sperduto, P. (2009). Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile. International Journal of Radiation Oncology, Biology, Physics, 75(4), 1162-1165. https://doi.org/10.1016/j.ijrobp.2008.12.054

Twenty-Year Survival in Glioblastoma : A Case Report and Molecular Profile. / Sperduto, Christina Maria; Chakravarti, Arnab; Aldape, Ken; Burger, Peter; Papermaster, Gail Bender; Sperduto, Paul.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 75, No. 4, 15.11.2009, p. 1162-1165.

Research output: Contribution to journalArticle

Sperduto, CM, Chakravarti, A, Aldape, K, Burger, P, Papermaster, GB & Sperduto, P 2009, 'Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile', International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 4, pp. 1162-1165. https://doi.org/10.1016/j.ijrobp.2008.12.054
Sperduto, Christina Maria ; Chakravarti, Arnab ; Aldape, Ken ; Burger, Peter ; Papermaster, Gail Bender ; Sperduto, Paul. / Twenty-Year Survival in Glioblastoma : A Case Report and Molecular Profile. In: International Journal of Radiation Oncology, Biology, Physics. 2009 ; Vol. 75, No. 4. pp. 1162-1165.
@article{bcde0c6d1d804d54bbdf8d061f8d6c02,
title = "Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile",
abstract = "Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.",
keywords = "Glioblastoma, Molecular Profile, Outcomes, Survival",
author = "Sperduto, {Christina Maria} and Arnab Chakravarti and Ken Aldape and Peter Burger and Papermaster, {Gail Bender} and Paul Sperduto",
year = "2009",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2008.12.054",
language = "English (US)",
volume = "75",
pages = "1162--1165",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Twenty-Year Survival in Glioblastoma

T2 - A Case Report and Molecular Profile

AU - Sperduto, Christina Maria

AU - Chakravarti, Arnab

AU - Aldape, Ken

AU - Burger, Peter

AU - Papermaster, Gail Bender

AU - Sperduto, Paul

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.

AB - Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.

KW - Glioblastoma

KW - Molecular Profile

KW - Outcomes

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=70449730262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449730262&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.12.054

DO - 10.1016/j.ijrobp.2008.12.054

M3 - Article

VL - 75

SP - 1162

EP - 1165

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -